Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Study has been completed and is in the data analysis and manuscript writing phase of the project.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Medtronic
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• Adult male and non-pregnant female patients scheduled for elective cardiac surgery requiring CPB will be eligible for enrollment.

Exclusion Criteria:

• Age less than 18 or greater than 90 years; emergency surgery

• Circulatory arrest

• Combined non-cardiac procedures such as carotid endarterectomy

• Congenital heart repair

• Off-CPB coronary artery bypass grafting (CABG)

• Clotting disorder

• Fibrinolytic agents (e.g. streptokinase), severe hepatic disease

• Aprotinin use

• Cooling < 28 degrees C during CPB

• Dialysis dependent renal failure; and

• Platelet receptor GP3a/2b antagonists medication received within 48 hours of surgery. Patients that are not receiving tranexamic acid (TA) intraoperatively will be excluded.